ASHMOME2023
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Review more from the post-hoc time-dependent analysis of the phase III Simplify-1, Simplify-2, and MOMENTUM trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.